Novo Nordisk shares rise after Wegovy obesity pill launch
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan.…
Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead – MarketWatch
Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead MarketWatchThe Truth…
Smoking cessation drug shows promise for treating cannabis use disorder
A new randomized controlled trial has found promising evidence that the smoking cessation medication varenicline (Chantix/Champix) can help…
Investor Noubar Afeyan warns against a backlash to science in the U.S.
SAN FRANCISCO — Noubar Afeyan, one of biotech’s top investors, warned in an annual letter that a backlash…
Johnson & Johnson, U.S. agree on drug discounts, new plants
Key Terms
tariffs
regulatory
Tariffs are taxes imposed by a government on goods…
Kennedy’s SSRI rhetoric fuels distrust amid teen mental health crisis
While his war on vaccines may be getting more attention, health secretary Robert F. Kennedy Jr. is coming…
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the…
Novo Nordisk beyond weight loss has investors wary, scientists hopeful
Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood…
LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs
NEW YORK, December 29, 2025, 17:45 ET — After-hours Shares of Eli Lilly and Company (LLY) were up…
Pill version of Novo Nordisk’s Wegovy approved, possibly widening access
The Food and Drug Administration on Monday approved the oral version of Novo Nordisk’s injectable weight loss drug…
Nasal spray sold nationwide recalled. See impacted products.
Something you bought was just recalled. What does that mean? What happens when something you purchase is recalled?…
Pharma’s ‘Dr. Optimistic’ is worried about the industry’s future
In July 2006, The New York Times sent young reporter Alex Berenson to Pfizer to interview me about…